Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. more
Time Frame | MNPR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 23.46% | -2.06% | -0.55% |
1-Month Return | 62.28% | -1.92% | 2.72% |
3-Month Return | 659.9% | -10.4% | 7.66% |
6-Month Return | 624.06% | -4.6% | 10.15% |
1-Year Return | 1753.87% | 4.06% | 27.53% |
3-Year Return | 51.98% | 1.94% | 32.31% |
5-Year Return | -77.4% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 122.40K | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | 122.40K | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | 100.00% | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.32M | 6.51M | 9.13M | 10.54M | 8.83M | [{"date":"2019-12-31","value":41.03,"profit":true},{"date":"2020-12-31","value":61.77,"profit":true},{"date":"2021-12-31","value":86.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.81,"profit":true}] |
Operating Income | (4.32M) | (6.51M) | (9.13M) | (10.54M) | (8.83M) | [{"date":"2019-12-31","value":-432376100,"profit":false},{"date":"2020-12-31","value":-650887500,"profit":false},{"date":"2021-12-31","value":-912724800,"profit":false},{"date":"2022-12-31","value":-1053687700,"profit":false},{"date":"2023-12-31","value":-883123500,"profit":false}] |
Total Non-Operating Income/Expense | 197.77K | 286.20K | 48.05K | 42.48K | 772.66K | [{"date":"2019-12-31","value":25.6,"profit":true},{"date":"2020-12-31","value":37.04,"profit":true},{"date":"2021-12-31","value":6.22,"profit":true},{"date":"2022-12-31","value":5.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.22M) | (6.30M) | (9.10M) | (10.52M) | (8.40M) | [{"date":"2019-12-31","value":-422487400,"profit":false},{"date":"2020-12-31","value":-630457300,"profit":false},{"date":"2021-12-31","value":-910322400,"profit":false},{"date":"2022-12-31","value":-1051563800,"profit":false},{"date":"2023-12-31","value":-840219600,"profit":false}] |
Income Taxes | (98.89K) | (81.90K) | (24.02K) | (21.24K) | (8.83K) | [{"date":"2019-12-31","value":-9888700,"profit":false},{"date":"2020-12-31","value":-8190200,"profit":false},{"date":"2021-12-31","value":-2402400,"profit":false},{"date":"2022-12-31","value":-2123900,"profit":false},{"date":"2023-12-31","value":-883123,"profit":false}] |
Income After Taxes | (4.13M) | (6.22M) | (9.08M) | (10.49M) | (8.39M) | [{"date":"2019-12-31","value":-412598700,"profit":false},{"date":"2020-12-31","value":-622267100,"profit":false},{"date":"2021-12-31","value":-907920000,"profit":false},{"date":"2022-12-31","value":-1049439900,"profit":false},{"date":"2023-12-31","value":-839336477,"profit":false}] |
Income From Continuous Operations | (4.22M) | (6.30M) | (9.10M) | (10.52M) | (9.48M) | [{"date":"2019-12-31","value":-422487400,"profit":false},{"date":"2020-12-31","value":-630457300,"profit":false},{"date":"2021-12-31","value":-910322400,"profit":false},{"date":"2022-12-31","value":-1051563800,"profit":false},{"date":"2023-12-31","value":-948461900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.13M) | (6.22M) | (9.08M) | (10.49M) | (8.40M) | [{"date":"2019-12-31","value":-412598700,"profit":false},{"date":"2020-12-31","value":-622267100,"profit":false},{"date":"2021-12-31","value":-907920000,"profit":false},{"date":"2022-12-31","value":-1049439900,"profit":false},{"date":"2023-12-31","value":-840219600,"profit":false}] |
EPS (Diluted) | (0.38) | (0.59) | (0.74) | (0.83) | (0.61) | [{"date":"2019-12-31","value":-38,"profit":false},{"date":"2020-12-31","value":-59,"profit":false},{"date":"2021-12-31","value":-74,"profit":false},{"date":"2022-12-31","value":-83,"profit":false},{"date":"2023-12-31","value":-61,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MNPR | |
---|---|
Cash Ratio | 5361.35 |
Current Ratio | 5405.50 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MNPR | |
---|---|
ROA (LTM) | -53.45% |
ROE (LTM) | -102.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MNPR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MNPR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 28.49 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Monopar Therapeutics Inc (MNPR) share price today is $29.94
Yes, Indians can buy shares of Monopar Therapeutics Inc (MNPR) on Vested. To buy Monopar Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Monopar Therapeutics Inc (MNPR) via the Vested app. You can start investing in Monopar Therapeutics Inc (MNPR) with a minimum investment of $1.
You can invest in shares of Monopar Therapeutics Inc (MNPR) via Vested in three simple steps:
The 52-week high price of Monopar Therapeutics Inc (MNPR) is $38.5. The 52-week low price of Monopar Therapeutics Inc (MNPR) is $1.54.
The price-to-earnings (P/E) ratio of Monopar Therapeutics Inc (MNPR) is
The price-to-book (P/B) ratio of Monopar Therapeutics Inc (MNPR) is 28.49
The dividend yield of Monopar Therapeutics Inc (MNPR) is 0.00%
The market capitalization of Monopar Therapeutics Inc (MNPR) is $161.92M
The stock symbol (or ticker) of Monopar Therapeutics Inc is MNPR